Introduction {#Sec1}
============

Patients diagnosed with perihilar cholangiocarcinoma (PHC), distal cholangiocarcinoma (DCC), and pancreatic cancer (PC) typically present with malignant biliary obstruction (MBO), which is one of the crucial reasons for the failure of surgery \[[@CR1]\]. Preoperative biliary drainage (PBD) is deemed to improve jaundice before surgery and decrease postoperative morbidity and mortality, although it remains controversial \[[@CR2]--[@CR4]\]. Furthermore, either percutaneous transhepatic biliary drainage (PTBD) or endoscopic biliary drainage (EBD) is the best strategy for resectable MBO is also a question \[[@CR5]--[@CR9]\].

Seeding metastasis (SM) is rarely refereed worldwide, but it has been reported frequently in Japan \[[@CR10]--[@CR17]\]. The incidence of SM in Japan was reported to range from 4.0 to 40.4% \[[@CR10]--[@CR17]\], which is no longer an "unusual" contingency. EBD was reported repeatedly to superior to PTBD in the prophylaxis of SM \[[@CR10]--[@CR17]\], but it was contradicted by a multicenter, retrospective study derived from US-Euro \[[@CR18]\]. Hence, a systematic review is warranted to evaluate the incidence of SM between EBD and PTBD in the procedure of PBD for patients with MBO.

Materials and methods {#Sec2}
=====================

Literature search {#Sec3}
-----------------

A comprehensive search was conducted by two independent researchers to clarify all published researches of PBD for preoperative obstructive jaundice. English electronic databases such as PubMed, MEDLINE, the Cochrane Library, and Web of Science were used to seek the literature, from Nov 1990 to Mar 2018. Keywords including "preoperative biliary drainage" and "malignant biliary obstruction" combined with free text words such as "percutaneous transhepatic biliary drainage" or "endoscopic biliary drainage" or "seeding metastasis" appeared in the electronic search.

Selection criteria {#Sec4}
------------------

Inclusion criteria are as follows: (1) cohort studies and randomized controlled trials were both considered, (2) PBD either PTBD or EBD for patients with MBO, (3) the primary endpoint was SM, and (4) sufficient data such as the baseline of characteristic were depicted.

Exclusion criteria are as follows: (1) in vitro or animal studies; (2) case reports, letters, reviews, and conference reports; (3) studies based on overlapping cohorts derived from the same center; and (4) sample size was not more than 20.

In case of results reported from the same center more than once, the latest was extracted.

Data extraction {#Sec5}
---------------

Predefined forms including baseline characteristics and outcomes were extracted from each study by Nanping Lin and Fuli Xin independently and then assessed by Lei Wang, Nanping Lin, and Fuli Xin. In the case of disagreement, a third investigator intervened for a conclusion.

Intervention and outcome definition {#Sec6}
-----------------------------------

PTBD (percutaneous transhepatic biliary drainage), including external drainage and internal drainage (percutaneous transhepatic biliary stent, PTBS), is depicted in Table [2](#Tab2){ref-type="table"}.

EBD (endoscopic biliary drainage), including external drainage such as endoscopic nasobiliary drainage (ENBD) and internal drainage (endoscopic biliary stent, EBS), is also depicted in Table [2](#Tab2){ref-type="table"}.

The mean interval between surgery and onset of the recurrence (SM) is depicted in Table [1](#Tab1){ref-type="table"}.Table 1Clinicopathological characteristics of trials includedStudyCountryStudy yearDesign of studiesFollow-up(months)Tumor typePTBDEBDOutcome indicatorsNo.TBIL (mg/dl)Histologic gradeTumor locationNo.TBIL (mg/dl)Histologic gradeTumor locationPoorly differentiatedPoorly differentiatedKawakami et al. \[[@CR10]\]Japan1999--2009RCS60PHC4812.0--I 4II 12IIIa 8IIIb 8IV 16809.6--I 15II 22IIIa 16IIIb 11IV 16①, ②Hwang et al. \[[@CR19]\]Korea1985--2002RCS120PHC171------62------①, ②Murakami et al. \[[@CR11]\]Japan1998--2013RCS60PC20--14--73--47--①, ②, ③Hirano et al. \[[@CR12]\]Japan2000--2008RCS160PHC678.4--I 5II 16IIIa 13IIIb 13IV 20745.2--I 15II 21IIIa 12IIIb 16IV 10①, ②, ③Komaya et al. \[[@CR13]\]Japan2001--2010RCS60DCC1897.4117Middle 53Low 1361874.7123Middle 61Low 126①, ②, ③Uemura et al. \[[@CR14]\]Japan2001--2012RCS120PC166--163--407--392--①, ②, ③, ④Wiggers et al. \[[@CR18]\]Netherland/USA1991--2012RCS60PC8811.2--I 8II 11IIIa 30IIIb 18IV:191573.2--I 41II 23IIIa 44IIIb 28IV 16①, ③Komaya et al. \[[@CR15]\]Japan2003--2012RCS60PHC168--123I/II/III 77IV 91152--113I/II/III 92IV 60①, ②, ③Higuchi et al. \[[@CR16]\]Japan2000--2013RCS12\~60PHC87--58I/II/III 50IV 3776--52I/II/III 44IV 32①, ②Miura et al. \[[@CR17]\]Japan1987--2015RCS60DCC253.712--632.432--①, ②Bismuth's classification: subtypes I, II, III, and IV; outcome indicators: ① PTBD catheter tract recurrence, ② pleural dissemination on the right side alone, ③ peritoneal dissemination, and ④ intrahepatic metastasis (only for PC)*TBIL* total bilirubin, *BC* Bismuth classification, *PHC* perihilar cholangiocarcinoma, *DCC* distal cholangiocarcinoma, *PC* pancreatic head carcinoma, *RCS* retrospective cohort studies, *NOS* Newcastle-Ottawa Scale, "--" not mentioned

SM was extracted directly from the original studies and was different from each other. The types of SM were as follows: (1) PTBD catheter tract recurrence, (2) pleural dissemination on the right side alone, (3) peritoneal dissemination, and (4) intrahepatic metastasis (only for PC) \[[@CR10], [@CR14]\].

When it was hard to distinguish tube-related SM with peritoneal metastasis, data was merged and subgroup analysis was avoided.

Quality assessment {#Sec7}
------------------

Considering all of the studies were retrospective cohort studies, quality assessment was assessed by the Newcastle-Ottawa Scale (NOS). Studies scored as ≥ 6 were considered of high quality.

Statistical analysis {#Sec8}
--------------------

The systematic review was registered at <http://www.crd.york.ac.uk> (122086) and performed using RevMan version 5.3 and Stata 14. Considering the apparent heterogeneity among different studies, such as different strategies of PBD, the stent material of biliary drainage, and the severity of obstructive jaundice, the random-effects model was used to compare the incidence of seeding metastasis between PTBD and EBD \[[@CR20]\]. Odds ratios (ORs) were for the dichotomous outcomes, followed with 95% confidence intervals (CI). Publication bias was evaluated by visually assessing the asymmetry of an inverted funnel plot and then was supported quantitatively by Egger's tests.

Results {#Sec9}
=======

Base characteristic of the included studies {#Sec10}
-------------------------------------------

Initially, 106 reports were identified by two independent reviewers. Twelve articles were excluded after duplicate removal by NoteExpress 3.1. After browsing titles and abstracts, 83 records were excluded. Among the remaining 11 articles, one record was excluded for lack of enough cases. Finally, 10 reports remained, including 6 studies of PHC \[[@CR10], [@CR12], [@CR15], [@CR16], [@CR18], [@CR19]\], 2 of DCC, and 2 of PC \[[@CR11], [@CR14]\]. In total, 2464 patients were enrolled in this meta-analysis, with 1379 cases in the EBD group and 1085 cases in the PTBD group (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of the study selection process for meta-analysis

The characteristic and quality of the included trials are shown in Table [1](#Tab1){ref-type="table"}. All the studies included in this meta-analysis were nonrandomized studies and were assessed by NOS. The scores ranged from 6 to 9, which indicated that all the studies were of high quality (Table [2](#Tab2){ref-type="table"}).Table 2Newcastle-Ottawa quality assessment of the included studiesStudySelectionComparabilityOutcomeScoresRepresentativeness of the exposed cohortSelection of the non-exposed cohortAscertainment of exposureOutcome of interest was presentedAssessment of outcomeFollow-up long enough for outcomes to occurAdequacy of follow-up of cohortsKawakami et al. \[[@CR10]\]★★★★★★★★8Hwang et al. \[[@CR19]\]★★★★★★★7Murakami et al. \[[@CR11]\]★★★★★★★7Hirano et al. \[[@CR12]\]★★★★★★★7Komaya et al. \[[@CR13]\]★★★★★★★★8Uemura et al. \[[@CR14]\]★★★★★★★★8Wiggers et al. \[[@CR18]\]★★★★★★6Komaya et al. \[[@CR15]\]★★★★★★★★★9Higuchi et al. \[[@CR16]\]★★★★★★★★★9Miura et al. \[[@CR17]\]★★★★★★★7^★^Score of the paper got after assessment

Comparison of SM incidence between EBD and PTBD for resectable MBO {#Sec11}
------------------------------------------------------------------

SM was reported in all the included studies \[[@CR10]--[@CR19]\], and results showed that there were significant differences in the rates of seeding metastasis between EBD and PTBD (10.5% vs. 22.0%, OR = 0.35, 95% CI 0.23\~0.53, *P* \< 0.001, Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plots of the seeding metastasis rates

Subgroup analysis of different SM incidences between EBD and PTBD for resectable MBO {#Sec12}
------------------------------------------------------------------------------------

SM was divided into peritoneal metastasis and tube-related seeding metastasis, and subgroup results showed that EBD was superior to PTBD both in peritoneal metastasis \[[@CR11]--[@CR15], [@CR17], [@CR18]\] (10.0% vs. 20.2%, OR = 0.42, 95% CI 0.31\~0.57, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}(a)) and tube-related SM \[[@CR10], [@CR12]--[@CR15], [@CR17]--[@CR19]\] (2.0% vs. 6.7%, OR = 0.17, 95% CI 0.10\~0.29, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}(b)).Fig. 3Subgroup analysis of (**a**) peritoneal metastasis and (**b**) tube-related seeding metastasis

Subgroup analysis of SM incidences between EBD and PTBD for different MBO {#Sec13}
-------------------------------------------------------------------------

PHC, DCC, and PC were the mainly pathogenies for MBO, and subgroup results showed that, in the prevention of SM, EBD was superior to PTBD in PHC \[[@CR10], [@CR12], [@CR15], [@CR16], [@CR18], [@CR19]\] (7.8% vs. 17.1%, OR = 0.27, 95% CI 0.13\~0.56, *P* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}(a)), DCC \[[@CR13], [@CR17]\] (6% vs. 18.2%, OR = 0.32, 95% CI 0.17\~0.60, *P* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}(b)), and PC \[[@CR11], [@CR14]\] (15.6% vs. 40.3%, OR = 0.27, 95% CI 0.19\~0.40, *P* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}(c)).Fig. 4Subgroup analysis of seeding metastasis rates derived from (**a**) PHC, (**b**) DCC, and (**c**) PC

Publication bias {#Sec14}
----------------

Funnel plot and Egger's tests were used to detect the publication bias of our meta-analysis. A total of 10 studies \[[@CR10]--[@CR19]\] evaluating the seeding metastasis rate of MBO patients treated with EBD or PTBD exhibited a basically symmetrical funnel plot (Fig. [5](#Fig5){ref-type="fig"}a) and yielded an Egger's test score of *P* = 0.409 (Fig. [5](#Fig5){ref-type="fig"}b).Fig. 5**a**, **b** Publication bias and sensitivity analysis

Discussion {#Sec15}
==========

This is the first systematic review focusing on the incidence of SM related to PBD for resectable MBO. A total of 10 studies with 2230 patients comparing the incidence of SM between PTBD and EBD were included in this study. Meta-analysis showed that EBD was associated with fewer SM than PTBD in the procedure of PBD for resectable MBO (10.5% vs. 22.0%, *P* \< 0.00001). Hence, we concluded that EBD could be considered in patients with resectable MBO.

PHC, DCC, and PC are typically present with biliary obstruction, which often increases the risk of perioperative mortality and morbidity \[[@CR21], [@CR22]\]. Palliative biliary drainage has been repeatedly confirmed to be efficient in the improvement of prognosis for patients with unresectable MBO \[[@CR23], [@CR24]\], but it still remains controversial whether patients with resectable MBO would be benefited from PBD \[[@CR2]--[@CR4]\]. Furthermore, whether either PTBD or EBD is better is another puzzle \[[@CR5]--[@CR9]\], although both have been conducted prevalently worldwide. Short-term outcomes, such as pancreatitis, bile leakage, and clinical and technique success rates, are the common indicators to compare the efficacy and safety between PTBD and EBD. From this aspect, EBD has been confirmed superior to PTBD by several meta-analyses \[[@CR25]--[@CR27]\]. Long-term outcome of PBD was rarely taken into consideration of the strategy for patients with MBO, but the superiority of EBD in the overall survival was reconfirmed in our previous meta-analysis \[[@CR28]\].

SM is rarely reported globally, but it was reported as high as 4.0\~40.4% in Japan \[[@CR10]--[@CR17]\]. Reasons are as follows: (a) preoperative PTBD longer than 60 days was associated with an increased risk of the SM \[[@CR29]\], (b) repeated attempts at PTBD \[[@CR29], [@CR30]\], and (c) multiple plastic stents were used rather than single one \[[@CR29], [@CR30]\]. In this study, eight included studies came from Japan \[[@CR10]--[@CR17]\], and the total incidence of SM (18.4%) was higher than that from Korea \[[@CR19]\] (2.0%) and comparable with Netherland-USA \[[@CR18]\] (16.7%). In the view of statistical data, SM was no longer an incident. Hence, the issue of SM deserved much more attention in clinical.

Theoretically, EBD is unlikely to cause SM. In this study, the incidence of SM is much lower in the EBD group than that in the PTBD group (10.5% vs. 22.0%, *P* \< 0.001). Potential mechanism of increased PTBD-related SM lied in that as follows: (1) tumor cells derived from the PTBD fluid drainage were reported to be more than those from the EBD \[[@CR19]\], which indicated that PTBD was much more likely to cause tumor diffusion. (2) PTBD was performed conventionally in the right liver, where the liver, peritoneum, diaphragm, pleura, and subcutaneous tissue were very close to each other anatomically \[[@CR17]\], which offered an appropriate environment for SM. Hence, Takahashi et al. \[[@CR29]\] recommended that PTBD should be performed in the left. (3) The general condition was usually much poorer in the patient intended to conduct PTBD, which meant a higher risk for SM.

The location of the MBO might be taken into consideration to decide an appropriate PBD. The recommended level of PTBD is higher than that of EBD for PHC according to the Chinese guideline (IIA vs. IIB) \[[@CR31]\], but it remains controversial for DCC and PC in most of the guidelines \[[@CR5], [@CR6], [@CR8]\]. In this study, the incidences of SM differed significantly among PHC, DCC, and PC (16.2% vs. 11.6%, and 22.5%), partly owing to varied aggressive characteristics of different cancers. However, subgroup analyses which were stratified by PHC, DCC, and PHC showed that the incidences of SM were lower in the EBD groups than those in the PTBD groups (7.8% vs. 11.7%, *P* \< 0.001; 6.0% vs. 18.2%, *P* \< 0.001; 15.6% vs. 40.3%, *P* \< 0.001; respectively), which indicated that EBD was superior to PTBD in the prevention of SM regardless of the location of MBO.

However, we felt puzzled for the mechanism of SM caused by EBD. Technically, EBD was unlikely to cause peritoneal metastasis unless intestinal perforation occurred in the procedure of EBD, especially in the experienced centers. In this study, the overall incidence of tube-related SM in the EBD group is 2.0%. Theoretically, EBD was unlikely to cause peritoneal SM, because the whole procedure of EBD was conducted inside the biliary duct. In this study, we divided SM into tube-related SM and peritoneal SM, and subgroup analysis showed that both the rate of tube-related SM and peritoneal metastasis decreased significantly in the EBD group (2.0% vs. 6.7%, *P* \< 0.001; 10.0% vs. 20.2%, *P* \< 0.001; respectively). Hence, we concluded that EBD was superior to PTBD in the prophylaxis of SM, although the definition of SM remained controversial.

There were several limitations in this study. First, there were no RCTs included in this meta-analysis, which made the conclusion sound weaken because cohort data had selection bias. Second, studies included in this meta-analysis were nearly from Japan, which indicated obvious regional bias. Third, PTBD was available when EBD failed, but those patients belonged to which group remained inconsistent \[[@CR15], [@CR19]\]. Bias could be also due to the following: (a) the requirement for an alternative drainage procedure due to therapeutic or technical failures was likely higher in the EBD group compared to patients undergoing preoperative PTBD and (b) Bismuth type III and IV tumors as compared to type I and II tumors were potentially better decompressed percutaneously, especially in the presence of complex strictures. Fourth, the definition of SM varied from each other due to the lack of a golden standard, for example, intrahepatic metastasis belonged to PBD-related seeding metastasis in PC \[[@CR14]\], but as for PHC and DCC, it tended to be rich in contradiction. Fifth, technical parameters of either PTBD or EBD, such as the procedure of PBD and the stent material, were different from each center, which indicated an inevitable heterogeneity and weaken the reliability. Sixth, the severity of obstructive jaundice, i.e., the level of preoperative serum bilirubin, was far from consistency, and caution should be taken when interpreting these results. The last but not the least, it was hard to avoid publication bias, because the journals tend to publish positive results.

In summary, we concluded that EBD was superior to PTBD for resectable MBO in the prophylaxis of SM, but there were currently not enough evidences. In the future, working out the definition of SM related to PBD is the urgent affair.
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